Disc Medicine to Participate in Upcoming Investor Conferences
Disc Medicine to Participate in Upcoming Investor Conferences
Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit .WATERTOWN, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will present at two upcoming investor conferences:
馬薩諸塞州沃特敦，2024年11月13日（環球新聞通訊社）——Disc Medicine, Inc. (納斯達克:IRON)是一家臨床階段的生物製藥公司，專注於爲患有嚴重血液疾病的患者發現、開發和商業化新型治療方法，今天宣佈公司管理層將在即將舉行的兩個投資者會議上進行介紹：
- Stifel 2024 Healthcare Conference on Tuesday, November 19th at 8:35 a.m. ET.
- 斯蒂費爾2024年醫療會議將於11月19日（星期二）上午8:35舉行。
- Jefferies London Healthcare Conference on Thursday, November 21st at 9:30 a.m. GMT.
- 傑弗裏倫敦醫療會議將於11月21日（星期四）上午9:30舉行。
A live webcast of the presentations will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available after the event.
演講的直播網絡廣播將在公司的投資者關係網頁ir.discmedicine.com上提供，活動結束後將提供錄製回放。
About Disc Medicine
Disc Medicine (NASDAQ:IRON) 是一家臨床階段的生物製藥公司，致力於發現，開發和商業化新型治療嚴重血液病患者的藥物。我們正在構建創新的潛在首個治療方案的組合，旨在通過靶向紅血球生物學的基本生物途徑，特別是血紅素生物合成和鐵穩態，治療廣泛的血液病。
Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit .
Disc Medicine（納斯達克：IRON）是一家臨床階段的生物製藥公司，致力於爲嚴重血液疾病患者發現、開發和商業化新型治療方法。我們正在建立一個創新的產品組合，可能是首個治療候選品，旨在通過靶向紅細胞生物學的基本生物途徑，尤其是血紅素生物合成和鐵離子穩態來應對廣泛的血液學疾病。更多信息請訪問。
Media Contact
媒體聯繫
Peg Rusconi
Deerfield Group
peg.rusconi@deerfieldgroup.com
Peg Rusconi
迪爾菲爾德集團
peg.rusconi@deerfieldgroup.com
Investor Relations Contact
投資者關係聯繫方式
Christina Tartaglia
Precision AQ
christina.tartaglia@precisionaq.com
Christina Tartaglia
Precision AQ
christina.tartaglia@precisionaq.com
譯文內容由第三人軟體翻譯。
